
    
      The primary objective of this study is to determine the plasma pharmacokinetics (PK) of
      quizartinib and its pharmacologically active metabolite AC886 after a single oral dose of 30
      mg in participants with moderate hepatic impairment (HI) (as defined by National Cancer
      Institute-Organ Dysfunction Working Group [NCI-ODWG] criteria) compared to the healthy
      control participants with normal hepatic function.
    
  